Systematic review of health economic models for assessment and diagnosis of dementia

Kwon, Joseph, Schoutens, Lisanne, Burden, Mitchell, Colam, Charlotte, Zhao, Sihao, Nezafat Maldonado, Behrouz, Blundell, Elizabeth, Krywonos, Anastasia, Jiang, Jingjing, Karagiannidou, Maria ORCID: 0000-0001-6996-4332, Jindra, Christoph, Vaci, Nemanja, Roberts, Nia, Wittenberg, Raphael ORCID: 0000-0003-3096-2721, Knapp, Martin ORCID: 0000-0003-1427-0215, Sanchez, Amparo Yovanna Castro, Roncancio-Diaz, Emilse, Potashman, Michele H, Thompson, Robin, Handels, Ron, Wolstenholme, Jane, Gray, Alastair M. and Landeiro, Filipa (2025) Systematic review of health economic models for assessment and diagnosis of dementia. Alzheimer’s & Dementia: Behavior & Socioeconomics of Aging, 1 (3). ISSN 2997-3805

Text (Alzheimer s Dementia Behavior Socioeconomics of Aging - 2025 - Kwon - Systematic review of health economic models for) - Published Version Available under License Creative Commons Attribution. Download (1MB)

Abstract

INTRODUCTION: Timely diagnosis of dementia is a public health priority to enable risk modification and treatment access. This study systematically identifies and critically appraises health economic models of dementia assessment and diagnosis. METHODS: Inclusion criteria were: any dementia stage; evaluated strategy(ies) for initial assessment/diagnosis of dementia; health economic evaluation using decision modeling. Ten databases were searched for 2000–2024. Philips checklist was applied for quality assessment. Narrative synthesis appraised methodological features and issued decision‐making recommendations. RESULTS: Thirty‐two studies were included. Six evaluated cerebrospinal fluid (CSF); 11 neuroimaging including amyloid‐targeting positron emission tomography; three blood‐based biomarkers; two genetic testing; and 10 early assessment/diagnosis strategies. Methodological limitations included non‐consideration of capacity constraints. Decision‐making recommendations generally affirmed current clinical guidelines: for example, CSF to confirm Alzheimer's disease is cost‐effective (incremental cost‐effectiveness ratio of £10,150 per quality‐adjusted life‐year gained vs. no use). DISCUSSION: Methodological appraisal and decision‐making recommendations should assist model development and evidence‐based dementia diagnosis.

Item Type:	Article
Additional Information:	© 2025 The Author(s)
Divisions:	Care Policy and Evaluation Centre
Subjects:	R Medicine > RA Public aspects of medicine
Date Deposited:	30 Jun 2025 14:33
Last Modified:	18 Jul 2025 14:51
URI:	http://eprints.lse.ac.uk/id/eprint/128590

Actions (login required)

View Item